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OverviewBackground and remit
In 1995, the Osteoarthritis Research Society (later renamed the
Osteoarthritis (OA) Research Society International [OARSI]) con-
ducted a workshop on issues related to the design of clinical trials
in knee and hip OA. Individuals from academia, industry, and gov-
ernment regulatory agencies participated in the workshop. A
manuscript describing the process and results was published in
Osteoarthritis and Cartilage in 19961. Subsequently, Maheu and col-
leagues published a similar set of recommendations for conducting
clinical trials in hand OA2.
In 2012, the Board of Directors of the OARSI initiated a process to
update the recommendations for conducting clinical trials in knee,
hip, and hand OA. Much had happened since the initial recommen-
dations, including advances in magnetic resonance and other imag-
ing techniques, development and testing of local and systemic
biomarkers of joint metabolism, and evolution of scientiﬁc rigor
to address methodologic issues involved in the conduct of surgical
trials, non-pharmacologic trials, implementation trials, and pri-
mary prevention trials.
The goal of the OARSI Initiative on Recommendations for Con-
ducting Clinical Trials in Osteoarthritis was (1) to gain consensus
regarding clinical trials methodology in OA using currently
accepted processes, (2) to develop recommendations with associ-
ated rationale for various approaches to key issues, and (3) to pro-
pose strategies for an ongoing research agenda.Table I
Working Groups for Osteoarthritis Research Society International Initiative on Rec-
ommendations for Conducting Clinical Trials in Osteoarthritis
Working Group Chair/co-Chair
Statistical and design issues Elena Losina/Jonas Ranstam
Biomarkers Virginia Byers Kraus
Imaging: Knee, hip, hand David Hunter/Garry Gold
KNEE OA: structure and symptoms Timothy McAlindon/Thomas
Schnitzer
HIP OA: structure and symptoms Nancy Lane/Marc Hochberg
HAND OA: structure and symptoms Margreet Kloppenburg/Emmanuel
Maheu
Non-pharmacologic trials: diet and
exercise
Stephen Messier
Surgical Trials Jeffrey Katz
Rehabilitation Trials G Kelley Fitzgerald
Joint injury prevention Carolyn Emery
Implementation Trials Kelli AllenAdministrative structure and procedures
The administrative structure consisted of a Chair and co-Chair, a
Steering Committee, and a series of Working Groups, each
composed of a Chair, co-Chair and Members. Joanne M Jordan,
MD MPH of the University of North Carolina at Chapel Hill in the
United States was appointed Chair of the Initiative, and Yves Hen-
rotin, PhD of University of Liege, Belgium was appointed co-Chair.
The Steering Committee consisted of the Chair and co-Chair and
four additional individuals with experience in clinical trial design
and regulatory issues. These included Marc C Hochberg, MD MPH
of the University of Maryland School of Medicine in Baltimore,
Maryland; Timothy McAlindon, MDMPH of Tufts University School
of Medicine in Boston, Massachusetts; Lee Simon, MD, former Di-
rector of the Division of Analgesic, Anti-inﬂammatory and Ophthal-
mologic Drug Products within the Center for Drug Evaluation andhttp://dx.doi.org/10.1016/j.joca.2015.03.016
1063-4584/© 2015 Osteoarthritis Research Society International. Published by Elsevier LResearch of the Food and Drug Administration; and Kim Bennell,
PhD of the University of Melbourne, Australia.
Working groups were formed to deal with different aspects of
the task at hand, and chairs and co-chairs invited and appointed
(Table I). Broad international representation from academia, indus-
try, and government was sought to constitute the members of the
Working Groups. In all, approximately 100 individuals with exper-
tise in different aspects of OA participated in the Initiative. All indi-
viduals completed a conﬂict of interest statement per OARSI policy
for such initiatives (see below).
The Steering Committee devised an overall procedure for the
respective Working Groups to follow, with consensus procedures
varying somewhat among the Working Groups, depending upon
the breadth of the topic and the presence and extent of controversy
in the scientiﬁc literature. All groups thoroughly reviewed the liter-
ature, some performing systematic reviews where indicated.
Where appropriate, voting by the members of a Working Group
on speciﬁc recommendations occurred; in accordance with proce-
dures from the Ethics Committee of the OARSI, those individuals
with a signiﬁcant conﬂict of interest or owning companies with a
stake in the outcome of a speciﬁc recommendation, were not
permitted to vote. Strong recommendations regarding use or
non-use of a speciﬁc procedure or technique were made in the
face of overwhelming evidence. More common, however, dogmatictd. All rights reserved.
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of the rapidity with which scientiﬁc and technical advances occur.
The Steering Committee and chairs/co-chairs of each Working
Group met in-person at the 2013 and 2014 OARSI World Con-
gresses to review procedures and progress. Additionally, working
groups communicated in-person, by telephone, and by email.
Each Working Group submitted a detailed work plan to the Steer-
ing Committee for approval, including plans for literature review,
consensus procedures, and a research agenda. The working chairs
had the opportunity to consult the Steering Committee if any major
disagreement occurred in their working groups. The Working
Group on Statistical and Design Issues and the Imaging Working
Group served as sources of reference for the other groups. Posting
of critical appraisal manuscripts to a secure ﬁle-sharing website
allowed direct input by Working Group Committee members and
the Steering Committee. All manuscripts underwent review by
the Steering Committee before submission to the journal, after
which they underwent further peer review per the journal's usual
procedure.
Organization of this issue
This issue is divided into two parts. The ﬁrst part, composed
of six articles, deals with topics applicable to multiple types of
OA clinical trials: statistical design and reporting issues; regulato-
ry procedures; biomarker qualiﬁcation procedures; and musculo-
skeletal imaging relevant to OA of the knee, hip, and hand. The
second part deals with speciﬁc types of OA trials, including sepa-
rate papers on OA of the knee, hip, and hand; non-pharmacologic
trials, speciﬁcally, diet and exercise trials, rehabilitation trials,
and injury prevention trials; surgical trials; and implementation
trials.
Analytic, reporting, and regulatory issues
This special issue opens with an overview by Losina and col-
leagues of key analytic, design, and reporting issues involved in
the conduct of pharmacologic and non-pharmacologic OA trials.
Special attention is given to approaches to missing data, economic
analyses, and requirements for reporting. An abbreviated look at
regulatory requirements and procedures for product approval of
pharmaceuticals and devices follows. Advances in understanding
of the pathologic processes involved in OA initiation and progres-
sion have allowed soluble biomarker development to be considered
as potential critical components of an OA clinical trial. Kraus and
colleagues describe technical requirements for soluble biomarker
qualiﬁcation and validation. Importantly, this article does not
recommend speciﬁc biomarkers to be used in clinical trials, but
sets the stage for future results from the OA Biomarkers Initiative
and others that 1 day may allow early identiﬁcation of OA risk, se-
lection of participants into trials, and monitoring of drug response
and safety with soluble biomarkers.
Imaging
Three papers on imaging for OA of the knee, hip, and hand sum-
marize radiographic, magnetic resonance imaging, and ultrasound
techniques and requirements for use in structure-modiﬁcation tri-
als. These papers address issues such as detailed acquisition
methods and techniques; commonly encountered difﬁculties and
solutions; quality assurance and control procedures; measurement
methods and performance; recommendations for trials; and
research recommendations. Recognition of the rapid pace of tech-
nological innovation is crucial in these recommendations and is re-
ﬂected in the consensus voting on critical issues.Knee, hip and hand structure- and symptom-modiﬁcation trials
The next three articles are devoted to symptom- and structure-
modiﬁcation trial issues in the knee, hip, and hand, respectively.
McAlindon and colleagues propose 25 consensus-driven recom-
mendations regarding randomization, blocking and stratiﬁcation,
blinding, enhancing accuracy of patient-reported outcomes,
describing patient-reported and physical performance measures,
structural outcomes measures, biochemical biomarkers, and
reporting recommendations. Lane and Hochberg and the Working
Group on hip OA describe advances in radiographic andMRI assess-
ment of hip OA for structure-modiﬁcation trials, as well as issues for
symptom-modiﬁcation trials; their paper also reviews recent re-
sults on local and systemic biomarkers of joint metabolism in hip
OA. Kloppenburg and Maheu and colleagues provide a detailed
and updated review of recent developments in the assessment
and evaluation of hand OA. These inform the description of core
outcome measurement sets for trials in hand OA, methods and in-
struments to be used to assess symptoms and structure, and a
robust research agenda to move the ﬁeld forward.
Non-pharmacologic trials
Messier and the Working Group on Diet and Exercise interven-
tions provide a primer for design of non-pharmacologic trials and
speciﬁc design issues unique to these types of trials, with exam-
ples from the published literature. Surgical trials have several
unique challenges that are expertly reviewed by Katz and mem-
bers of the Surgical Trials Working Group. Rehabilitation trials
also have speciﬁc challenges to scientiﬁc integrity inherent in their
design; these are outlined by Fitzgerald and colleagues. Finally, an
example of primary prevention of OA is presented by Emery and
colleagues in their overview of joint injury prevention trials, and
Allen and colleagues describe challenges associated with imple-
mentation trials.
Summary
This special issue of Osteoarthritis and Cartilage represents the
combined expertise and work of many individual experts from
academia, industry, and regulatory agencies to inform the
research community about advances in clinical trial design and
execution and support key recommendations for structure- and
symptom-modiﬁcation trials in OA. It also outlines a research
agenda to inform future trial development. It is hoped that this
will provide a crucial resource for those interested in designing
and executing clinical trials of multiple different interventions
for OA, regulatory agencies, and those interested in moving the
research agenda forward for the betterment of people with OA
worldwide.
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